Generic Medicine Info
Should be taken with food.
Hypersensitivity. Moderate to severe hepatic impairment (Child-Pugh class B or C). Lactation. Concomitant administration with drugs that highly dependent on CYP3A for clearance or potent CYP3A inducers.
Special Precautions
Patient with diabetes mellitus, haemophilia A or B, risk factor for increased bleeding (e.g. trauma, surgery, other pathological conditions); sulfonamide allergy. Mild hepatic impairment (including chronic hepatitis B or C). Pregnancy. Monitoring Parameters Monitor total cholesterol and triglyceride at baseline and during therapy; LFT at baseline and frequently during therapy; viral load, CD4, glucose as clinically indicated. Monitor for signs and symptoms of hepatitis/hepatotoxicity.
Adverse Reactions
Significant: Fat redistribution (e.g. buffalo hump, breast enlargement, central obesity, cushingoid appearance, facial wasting, peripheral wasting), hyperglycaemia or diabetes mellitus, hyperlipidaemia, immune reconstitution syndrome, skin reaction (e.g. urticarial rash, maculopapular rash, photosensitivity). Gastrointestinal disorders: Abdominal distention, abdominal pain, diarrhoea, dyspepsia, flatulence, nausea, vomiting. General disorders and administration site conditions: Fatigue. Metabolism and nutrition disorders: Hypertriglyceridaemia. Nervous system disorders: Headache.
Potentially Fatal: Hepatotoxicity (e.g. hepatitis, hepatic failure), intracranial haemorrhage.
Drug Interactions
Increased serum concentration with fluconazole. May increase serum concentration of bosentan, fluticasone, midazolam (IV), rifabutin, trazodone, atorvastatin. Increased risk of QT prolongation, palpitations, sinus tachycardia with salmeterol. Decreased serum concentration with anticonvulsants (e.g. carbamazepine, phenobarbital, phenytoin). May decrease serum concentration of ethinyl estradiol, nucleoside reverse transcriptase inhibitors (e.g. abacavir, didanosine, zidovudine), protease inhibitors (e.g. amprenavir, lopinavir, saquinavir), dolutegravir, meperidine. May produce disulfiram-like reaction with metronidazole.
CIMS Class
ATC Classification
J05AE09 - tipranavir ; Belongs to the class of protease inhibitors. Used in the systemic treatment of viral infections.
Disclaimer: This information is independently developed by CIMS based on tipranavir from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in